Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

<p><strong>Background</strong> The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to es...

詳細記述

書誌詳細
主要な著者: Butler, CC, Hobbs, FDR, Gbinigie, OA, Rahman, NM, Hayward, G, Richards, DB, Dorward, J, Lowe, DM, Standing, JF, Breuer, J, Khoo, S, Petrou, S, Hood, K, Nguyen-Van-Tam, JS, Patel, MG, Saville, BR, Marion, J, Ogburn, E, Allen, J, Rutter, H, Francis, N, Thomas, NPB, Evans, P, Dobson, M, Madden, T-A, Holmes, J, Harris, V, Png, ME, Lown, M, van Hecke, O, Detry, MA, Saunders, CT, Fitzgerald, M, Berry, NS, Mwandigha, L, Galal, U, Mort, S, Jani, BD, Hart, ND, Ahmed, H, Butler, D, McKenna, M, Chalk, J, Lavallee, L, Hadley, E, Cureton, L, Benysek, M, Andersson, M, Coates, M, Barrett, S, Bateman, C, Davies, JC, Raymundo-Wood, I, Ustianowski, A, Carson-Stevens, A, Yu, L-M, Little, P
その他の著者: PANORAMIC Trial Collaborative Group
フォーマット: Journal article
言語:English
出版事項: Elsevier 2022

類似資料